Fibrosis and cirrhosis of liver
Conditions
Interventions
Experimental group: 4 patients with grades 2 and 3 acute-on-chronic liver failure who will receive bone marrow-derived mesenchymal stem cells associated with standard medical treatment. Control group:
Biological/vaccine
Sponsors
Hospital de Clínicas de Porto Alegre
Hospital de Clínicas de Porto Alegre
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: fulfilling ACLF diagnostic criteria and ACLF grade 2 or 3
Exclusion criteria
Exclusion criteria: patient’s or family member’s refusal; (b) hepatocellular carcinoma (HCC); (c) formal contraindicationfor liver transplantation (e.g. advanced heart or pulmonary disease); (d) pregnancy and lactation; (e) previous liver transplantation; (f) HIV co-infection; (g) ACLF grade 1; (h) patients admitted for elective procedures; (i) renal chronic disease requiring dialysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate mortality in the period of 28 and 90 days, verified by means of the Kaplain-Meier curves, from the observation of a variation post-intervention;Assess adverse effects, verified through clinical changes and vital signs, based on the observation of a post-intervention variation | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate liver function patterns (prothrombin time, bilirubins and albumin) and inflammatory markers (total leukocytes and C-reactive protein) in the pre- and post-infusions of mesenchymal stem cells compared to placebo | — |
Countries
Brazil
Contacts
Public ContactFernando;Fernando Schacher;Schacher
Hospital de Clínicas de Porto Alegre;Hospital de Clínicas de Porto Alegre
Outcome results
None listed